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of suspected community-acquired
pneumonia presenting to
the emergency department
Exclusions
Patients with hospital-acquired
pneumonia, active thoracic
malignancy, immunosuppression
or undergoing palliative care
n = 266
Patients with
community-acquired pneumonia
n = 1883
Tested for
Clostridium difficile infection 
n = 365 (19.4%)
Confirmed
C. difficile infection 
n = 61 (3.2%)
Figure 1 Flow chart illustrating the number of patients
included and excluded in the study.Introduction
Clostridium difficile is a Gram-positive, anaerobic, spore-
forming bacillus that colonizes or infects the colon, and
causes a spectrum of illnesses from relatively trivial diar-
rhoea to life-threatening pseudomembranous colitis. C.
difficile infection (CDI) is most frequently acquired within
healthcare facilities and is strongly associated with the
use of broad-spectrum antibiotic therapy.1 In recent years,
there has been a dramatic rise in the incidence of CDI in
many countries, including the UK, the USA and Australia.2e5
Indeed, despite improved control of CDI in the UK, there
were over 14,000 reported cases across all NHS Trusts in En-
gland between April 2014 and March 2015, with a corre-
sponding CDI rate of 41.0 per 100,000 bed days.6
Community-acquired pneumonia (CAP) is a major cause
of infectious morbidity and mortality in Western countries
and is a frequent indication for antibiotic administration
in hospitals.7 Broad-spectrum antibiotic prescribing,
particularly third-generation cephalosporin use, in CAP
has been linked to a C. difficile epidemic.8e10 With the
current increase in the number of hospitalizations for
CAP in Western countries, the risk of antibiotic-
associated complications is also rising.11
Recently, guidelines have attempted to reduce the
incidence of CDI as a consequence of CAP by promoting
restricted use of cephalosporins, clindamycin and fluoro-
quinolones, considered to be major drivers of CDI.1,12 Other
risk factors for CDI include increasing age, use of gastric
acid-suppressing medications, multiple comorbidities, and
inflammatory bowel disease.13 There is, however, a paucity
of data in populations with CAP. The incidence of CDI spe-
cifically in patients with CAP is unknown, and the contribu-
tion of CDI to mortality in CAP has not been reported. A
recent study of inpatient discharges from community hospi-
tals, which included patients with CAP, found that CDI was
associated with higher in-hospital mortality among patients
discharged for pneumonia or urinary tract infection.14
The aim of this longitudinal study was to assess the
incidence of and risk factors for CDI in a large cohort of
patients hospitalized with CAP.
Patients and methods
This is a secondary analysis of a prospective, observa-
tional cohort study of patients with CAP, conducted in two
large teaching hospitals in Edinburgh, UK (2005e2010),
serving a population of approximately 500,000 people.15
The Lothian Research Ethics Committee approved the
study.Inclusion and exclusion criteria
Patients were included if they had a diagnosis of CAP on
admission, defined as having a new radiographic infiltrate
and three or more of the following symptoms or signs:
cough, sputum production, haemoptysis, breathlessness,
fever, pleuritic chest pain, or signs consistent with
pneumonia on physical examination. Exclusion criteria
were: hospital-acquired pneumonia, active thoracic ma-
lignancy and immunosuppression (defined as use of oral
corticosteroids or other immunosuppressive drugs within
28 days before enrolment). Patients in whom active
treatment was not considered appropriate (e.g. those
receiving palliative care) were also excluded (Fig. 1).16,17
Patients with suspected healthcare-associated pneumonia
(HCAP; defined according to the 2005 guidelines of the In-
fectious Disease Society of America/American Thoracic
Society [IDSA/ATS])15,18 were not excluded, although risk
factors for HCAP were recorded and patients were classi-
fied as having CAP or HCAP according to the IDSA/ATS
guidelines.
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Antimicrobial therapy was at the discretion of the
attending physician, who was guided by a protocol based
on clinical severity.16 All antimicrobial treatment within 30
days of hospitalization with CAP, including antibiotic treat-
ment during the 14 days preceding admission, was re-
corded. For the analysis, antibiotics were grouped by drug
class (cephalosporins, amoxicillin/clavulanic acid, macro-
lides, fluoroquinolones, tetracyclines, carbapenems, piper-
acillin/tazobactam, narrow-spectrum penicillins). Duration
of antibiotic therapy was recorded as the number of whole
days of treatment with the same antibiotic within 30 days.
This included antibiotics administered before admission to
hospital and those administered in the 30 days after admis-
sion. Antibiotics used to treat CDI or received after CDI
diagnosis were identified and excluded from analyses of
antibiotic class and duration.
Testing for CDI infection
Testing for C. difficile was mandatory at the hospitals at
the time of this study. The protocol required that all pa-
tients reporting more than two loose stools per day (or
more stools than normal for them) provided a specimen
for a C. difficile toxin test (Techlab C. difficile Tox A/B II
kit; TechLab, Blackburg, VA, USA). CDI was defined as diar-
rhoea with a positive test for C. difficile toxin.
Outcomes
The primary outcome was the development of laboratory-
confirmed CDI. Secondary outcomes were 30-day and 1-
year mortality. Mortality was recorded for up to 1 year post-
discharge using electronic medical records linked to the
Scottish Register Office, which uses unique identifiers to
accurately record all deaths in Scotland.
Statistical analysis
Data were analysed using SPSS v.13 (SPSS Inc., Chicago, IL,
USA). To compare categorical data, the c2 test or Fisher’s
exact test (for comparisons involving fewer than 10 pa-
tients) was used. The ManneWhitney U test was used to
compare two groups of continuous data. To identify clinical
factors independently associated with CDI, all potential risk
factors that were considered to be clinically important, or
that were statistically significantly associated with CDI in
univariate analysis, were identified and entered into a
Cox proportional hazard model. We used time-dependent
Cox regression models to account for fluctuations in antibi-
otic exposure status during follow-up, and to account for
duration of hospitalization prior to CDI diagnosis. Results
are presented as estimate hazard ratios (HRs) and corre-
sponding 95% confidence intervals (CIs), with days of
follow-up until diagnosis of CDI as a time variable, and hos-
pitalization status and use of antibiotic treatments as time-
dependent variables. Multivariable models were con-
structed based on modelling studies by Peduzzi et al.,
who suggest a maximum of one covariate per 10 events.19Two regression analyses were performed because combina-
tion antibiotic therapy was common, potentially leading to
multicollinearity. In the first analysis, all predictors except
antibiotic class were included to establish the patient- and
treatment-related risk factors for CDI. In the second anal-
ysis, antibiotic classes (grouped as cephalosporins, amoxi-
cillin/clavulanic acid, macrolides, fluoroquinolones,
tetracyclines, carbapenems, piperacillin/tazobactam, nar-
row-spectrum penicillins) were individually included in
the models to determine the independent contribution of
antibiotic class to CDI risk. In sub-analyses, the additive ef-
fect of antibiotic combinations compared with monother-
apy was assessed using separate survival models and
estimates were compared using interaction testing.20 The
proportional hazards assumption was satisfied in each
model. A P value of less than 0.05 was considered to be sta-
tistically significant.
Results
Study cohort
Overall, 1883 patients with CAP were included in these
analyses (Fig. 1), and 30-day mortality was 9.0% (nZ 169).
Baseline demographic and clinical characteristics, and the
most frequently used antibiotic regimens are shown in
Table 1. The median age of patients was 68 years and 51%
were male. The most frequently used empiric antibiotics
were clarithromycin (58%), amoxicillin/clavulanic acid
(47%) and amoxicillin (35%). Overall, 24% of patients had
risk factors for HCAP.
C. difficile infection
Faecal samples from 365 patients (19.4%) were sent for
testing, indicating a high frequency of diarrhoea symptoms
in patients hospitalized with CAP. Overall, 61 patients
(3.2%) had laboratory-confirmed CDI during the study
period. Rates of CDI varied annually from 1.5% in 2005 to
4.2% in 2006 and 3.3% in 2007, peaking at a rate of 5.1% in
2008. In 2009 and 2010, rates of CDI fell to 2.9% and 2.2%,
respectively.
Selected demographic, clinical and baseline character-
istics of patients who developed CDI compared with those
who did not develop CDI are shown in Table 2. There were
significant differences in the characteristics of patients in
these two groups; patients with CDI were older (median
age, 79 years vs. 67 years; P < 0.0001), had more severe
pneumonia (median pneumonia severity index [PSI] score,
4 vs. 3; P < 0.0001) and required longer periods of hospital-
ization (median, 30 days vs. 5 days; P < 0.0001). In those
patients with CDI, the median duration of hospitalization
prior to CDI diagnosis was 18 days and the median duration
of admission after CDI diagnosis was 14 days.
CDI was also significantly associated with longer duration
of antibiotic therapy (mean duration, 11.5 days for patients
with CDI vs. 10.2 days for those without CDI; P Z 0.002;
Table 2) and a higher number of antibiotics received
(mean, 2.6 for patients with CDI vs. 1.8 for those without
CDI; P < 0.0001). The most frequently used antibiotic
Table 1 Baseline demographic and clinical characteristics.
Characteristic Patients with
CAP (n Z 1883)
Demographics
Male 961 (51.0)
Age (years), median (IQR) 68 (62e79)
Active smoker 650 (34.5)
Active alcohol abuser 189 (10.0)
Comorbidities
COPD 496 (26.3)
Healthcare-associated pneumonia 451 (24.0)
Congestive cardiac failure 390 (20.7)
Diabetes mellitus 245 (13.0)
Cerebrovascular disease 191 (10.1)
Chronic renal failure 124 (6.6)
Liver disease 98 (5.2)
CAP severity on admission
PSI risk class IV and V 667 (35.4)
Altered mental state 281 (14.9)
ICU admission 181 (9.6)
Physical findings on admission
Temperature (C), median (IQR) 37.5 (36.9e38.4)
Hypotensiona 444 (23.6)
Heart rate (beats/minute),
median (IQR)
104 (89e118)
Respiratory rate
(breaths/minute), median (IQR)
25 (20e32)
SpO2, median (IQR) 94 (91e95)
Laboratory values
Arterial pH <7.35 247 (13.1)
White blood cells (109 cells/mL),
median (IQR)
14.2 (9.2e19.5)
Platelets (109 cells/mL), median (IQR) 244 (192e322)
Glucose (mg/dL), median (IQR) 117 (101e142)
Sodium (mEq/L), median (IQR) 137 (134e140)
Chest radiograph findings
Pleural effusion 385 (20.4)
Empiric antibiotic treatment
Clarithromycin 1099 (58.4)
Amoxicillin/clavulanic acid 893 (47.4)
Amoxicillin 652 (34.6)
Cephalosporins 305 (16.2)
Piperacillin/tazobactam 56 (3.0)
Doxycycline 55 (2.9)
Clindamycin 12 (0.6)
Ciprofloxacin 31 (1.6)
Meropenem 9 (0.5)
Vancomycin 16 (0.8)
Co-trimoxazole 10 (0.5)
Others 122 (6.5)
Clinical outcomes
Duration of hospitalization (days),
median (IQR)
5 (3e11)
In-hospital mortality 169 (9.0)
Data are shown as n (%) unless otherwise stated.
CAP, community-acquired pneumonia; COPD, chronic obstruc-
tive pulmonary disease; CXR, chest radiograph; ICU, intensive
care unit; IQR, interquartile range; PSI, pneumonia severity in-
dex; SpO2, oxygen saturation.
a Defined as systolic blood pressure <90 mmHg and/or dia-
stolic blood pressure <60 mmHg.
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clavulanic acid (63.9% of patients with CDI vs. 46.9% of
those without CDI; P < 0.009), with or without macrolides,
and regimens containing cephalosporins (27.9% of patients
with CDI vs. 15.8% of those without CDI; PZ 0.01). The ma-
jority of patients received multiple antibiotics (after
excluding those used to treat CDI). The most common com-
bination treatment was amoxicillin/clavulanic acid plus
clarithromycin (508 patients, 27%).
Congestive cardiac failure (P Z 0.007) and cerebrovas-
cular disease (P < 0.0001) were significantly more common
among patients with CDI than among those without CDI
(Table 2). In addition, 57.4% of patients with CDI had risk
factors for HCAP, compared with 22.8% of patients without
CDI (P < 0.0001). Of the risk factors recorded for HCAP, 26
patients had a history of recent hospitalization, 6 were
nursing home or care facility residents, 2 were receiving
dialysis for chronic renal failure, and 1 received home infu-
sion therapy.
In a multivariable analysis, independent risk factors for
CDI were identified as: age, total number of antibiotic
classes received, total duration of antibiotic therapy, and
the presence of one or more comorbidities (Table 3). The
time-dependent variable hospitalization status was
strongly associated with CDI diagnosis indicating patients
were at significantly higher risk while they remained in
hospital; this model did not include antibiotic class as a
variable. When antibiotic class was subsequently included
as an independent variable, there was a statistically sig-
nificant association between macrolides (HR, 1.77; 95%
CI, 1.03e3.03) and CDI, but no other statistically signifi-
cant associations at the level of antibiotic class were
identified (Table 3). Using interaction testing, there
were no significant differences in risk estimates between
amoxicillin/clavulanic acid and cephalosporins, macro-
lides or quinolones (P > 0.05 for all comparisons,
Table 3), consistent with the view that these antibiotics
confer similar risks of CDI. When repeating the analysis
using the total duration of exposure to each antibiotic
in a time-dependent analysis, similar results were
observed (Table 4). Proton pump inhibitors were excluded
from the models, as they were not significantly associated
with CDI in any of the current analyses (odds ratio [OR],
0.81; 95% CI, 0.41e1.57; P Z 0.5).
As combination therapy with macrolides is common in
CAP, we investigated whether the addition of clarithromy-
cin to any of the b-lactams (amoxicillin, amoxicillin/
clavulanic acid or cephalosporins) resulted in an increase
in CDI. Addition of clarithromycin to amoxicillin compared
with amoxicillin treatment alone was associated with a
non-significant increase in CDI (unadjusted HR, 1.31; 95%
CI, 0.47e3.68; P Z 0.6; adjusted HR, 1.19; 95% CI,
0.42e3.39; P Z 0.7). Addition of clarithromycin to amoxi-
cillin/clavulanic acid was associated with a significant in-
crease in CDI risk compared with amoxicillin/clavulanic
acid alone (unadjusted HR, 2.00; 95% CI, 1.00e4.02;
P Z 0.04; adjusted HR, 2.09; 95% CI, 1.04e4.21;
P Z 0.04). Fewer patients received cephalosporins, but
the corresponding HRs for the addition of clarithromycin
were 1.24 (95% CI, 0.47e3.31; P Z 0.6; unadjusted) and
1.08 (95% CI, 0.39e3.03; P Z 0.9; adjusted). There were
no significant differences in the risk factors for CDI between
Table 2 Baseline demographic and clinical characteristics of patients with CDI and those without CDI.
Potential risk factor for CDI Patients with CDI
(n Z 61)
Patients without CDI
(n Z 1822)
P value
Demographics, median (IQR)
Age, years 79 (71e83) 67 (50e77) <0.0001
Pneumonia severity index (PSI) score 4 (4e5) 3 (2e4) <0.0001
Duration of hospitalization (days) 30 (12e46) 5 (2e10) <0.0001
Antibiotic administration, mean (SD)
Duration of antibiotic therapy (days) 11.5 (3.5) 10.2 (3.1) 0.002
Number of antibiotic classes 2.6 (1.2) 1.8 (0.6) <0.0001
Antibiotic agents, n (%)
Cephalosporins 17 (27.9) 288 (15.8) 0.01
Narrow-spectrum penicillins 15 (24.6) 637 (35.0) 0.09
Amoxicillin/clavulanic acida 39 (63.9) 854 (46.9) 0.009
Macrolides 41 (67.2) 1058 (58.1) 0.1
Tetracyclines 2 (3.3) 53 (2.9) 0.9
Quinolones 5 (8.2) 26 (1.4) <0.0001
Piperacillin/tazobactam 14 (22.9) 42 (2.3) <0.0001
Comorbidities, n (%)
COPD 21 (34.4) 475 (26.1) 0.1
Congestive cardiac failure 21 (34.4) 369 (20.3) 0.007
Diabetes mellitus 4 (6.6) 241 (13.2) 0.1
Cerebrovascular disease 18 (29.5) 173 (9.5) <0.0001
Renal failure 7 (11.5) 117 (6.4) 0.1
Liver disease 5 (8.2) 93 (5.1) 0.3
Classification of disease, n (%)
Risk factors for healthcare-associated pneumonia 35 (57.4) 416 (22.8) <0.0001
CDI, Clostridium difficile infection; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; PSI, pneumonia severity in-
dex; SD, standard deviation.
a With or without macrolides.
C. difficile infection following pneumonia 49the subgroups of patients with risk factors for HCAP
(n Z 35) and those without such risk factors (n Z 26;
Table 4).
Contribution of CDI to clinical outcomes in CAP
Mortality in patients with CAP who developed CDI during
hospitalization was 21.3%, compared with 8.6% in patientsTable 3 Time-dependent Cox Proportional Hazards regression a
patients with CAP.
Risk factor
Baseline model
Age (per year)
Comorbidities (per additional comorbidity)
PSI class (per additional class)
Duration of antibiotic therapy (per day)
Number of antibiotic classes (per additional class)
Hospitalization status
Antibiotic classes (any exposure model)
Cephalosporins
Amoxicillin/clavulanic acid
Macrolides
Quinolones
Amoxicillin
CAP, community-acquired pneumonia; CDI, Clostridium difficile infecwithout CDI (P < 0.0001), rising to 42.6% after 1 year
(compared with 1-year mortality of 20.5% in those without
CDI [P < 0.0001] and 21.3% for all patients with CAP
[PZ 0.0001]). However, when adjusted for age, comorbid-
ities, and CAP severity using PSI scores, CDI was no longer
an independent predictor of 30-day mortality (HR, 1.68;
95% CI, 0.78e3.63; PZ 0.2). Variables independently asso-
ciated with 30-day mortality were: age (HR, 1.02 per year;nalysis of independent risk factors for CDI in a population of
Multivariate hazard ratio (95% CI) P value
1.06 (1.03e1.08) <0.0001
1.21 (0.91e1.60) 0.2
0.86 (0.65e1.12) 0.3
1.09 (1.00e1.19) 0.04
3.01 (2.32e3.91) <0.0001
13.1 (6.0e28.7) <0.0001
1.48 (0.83e2.63) 0.2
1.66 (0.98e2.83) 0.06
1.77 (1.03e3.03) 0.04
1.35 (0.53e3.41) 0.5
0.94 (0.52e1.72) 0.6
tion; CI, confidence interval.
Table 4 Time-dependent Cox Proportional Hazard regression analysis of duration of antibiotic exposure and risk of CDI in a
population of patients with CAP, and risk of CDI over time.
Risk factor Multivariate hazard ratio (95% CI) P value
Duration model (per day)
Cephalosporins 1.02 (0.91e1.14) 0.8
Amoxicillin/clavulanic acid 1.10 (1.05e1.15) <0.0001
Macrolides 1.13 (1.07e1.20) <0.0001
Quinolones 1.01 (0.93e1.10) 0.8
Amoxicillin 1.05 (0.99e1.12) 0.1
Sensitivity analysis excluding HCAP
Age (per year) 1.09 (1.04e1.14) <0.0001
Comorbidities (per additional comorbidity) 1.18 (0.76e1.84) 0.5
PSI class (per additional class) 0.74 (0.46e1.18) 0.2
Duration of antibiotic therapy (per day) 1.06 (0.93e1.21) 0.4
Number of antibiotic classes (per additional class) 3.07 (1.85e5.09) <0.0001
Hospitalization status 7.79 (2.57e23.6) <0.0001
Sensitivity analysis e HCAP only
Age (per year) 1.05 (1.02e1.08) 0.002
Comorbidities (per additional comorbidity) 1.33 (0.91e1.95) 0.2
PSI class (per additional class) 0.94 (0.67e1.32) 0.7
Duration of antibiotic therapy (per day) 1.08 (0.96e1.22) 0.2
Number of antibiotic classes (per additional class) 2.54 (1.84e3.51) <0.0001
Hospitalization status 17.7 (5.67e55.0) <0.0001
CAP, community-acquired pneumonia; CDI, Clostridium difficile infection; CI, confidence interval; HCAP, healthcare-associated
pneumonia.
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1.02e1.04; P < 0.0001).Discussion
Although C. difficile has been linked with antibiotic treat-
ment for respiratory tract infections for more than a
decade, there have been no previous studies describing
the risk factors for CDI in a CAP population.8e10 This is sur-
prising, as management practices for lower respiratory
tract infections have changed substantially in response to
the rising incidence of CDI, particularly in the UK.21e23
These changes are specifically mentioned in the 2004 and
2009 updates of the British Thoracic Society guidelines for
CAP as a driver for reducing broad-spectrum antibiotic
consumption.24,25
Our results suggest that at least some CDI risk factors are
modifiable, and that some cases of CDI are therefore
preventable. Among the major risk factors identified in
our time-dependent regression models were duration of
antibiotic therapy and the number of antibiotic classes
used, both of which are modifiable to some degree. Not
surprisingly, given that CDI is most frequently a nosocomial
infection, patients were at much higher risk of acquiring
CDI during hospitalization than after hospital discharge.
Duration of hospital admission for CDI is also modifiable and
our analysis suggests that initiatives to reduce the length of
hospital stay for CAP may also impact on CDI risk. Strikingly,
however, we did not identify a strong relationship between
antibiotic class and CDI. Our data suggest that all of the
broad-spectrum antibiotics commonly used in CAP,
including amoxicillin/clavulanic acid, cephalosporins andquinolones, carry a similar level of risk. This is in contrast to
previous studies, which found a strong association between
an increased frequency of CDI and the use of cephalospo-
rins and clindamycin in particular.1,9 This may reflect the
dominance of only a few antibiotic classes in CAP, with
the majority of patients receiving b-lactams or cephalospo-
rins, with or without macrolides.22,23 Moreover, a recent
analysis of antibiotic prescribing policies and CDI rates in
NHS Trusts in England suggested that policies recommend-
ing the empiric use of broad-spectrum antibiotics in pa-
tients with CAP may be associated with higher rates of
CDI.26 Importantly, however, the study focussed on the hos-
pital policies and did not demonstrate a causal relationship
between antibiotic use and CDI, and did not assess factors
such as treatment duration or whether the use of broad-
spectrum antibiotics in patients with CAP was appropriate.
Interestingly, amoxicillin/clavulanic acid and macrolides
were the antibiotics most often associated with CDI in the
present cohort. National UK guidelines recommended re-
placing cephalosporins with amoxicillin/clavulanic acid in
part because of concerns about the risk of CDI.24,25 Howev-
er, our data suggest that this change did not substantially
reduce the frequency of CDI during 2005e2010; indeed,
the incidence of CDI substantially increased during the
period in which amoxicillin/clavulanic acid was replacing
cephalosporins as first-line therapy.27 CDI rates have subse-
quently declined in the UK, following concerted efforts to
improve antimicrobial-prescribing practices and initiatives
to prevent transmission in hospitals.6,28 In contrast, rates
of CDI remain high in North America.2,29 A recent, 46-
month, retrospective cohort study of 34,298 inpatients
from a large, acute care hospital in Canada reported an
incidence of CDI of 5.95 per 10,000 patient-days. Moreover,
C. difficile infection following pneumonia 51the study demonstrated that ward-level antibiotic prescrib-
ing was significantly associated with an increased risk of
CDI, with each 10% increase in antibiotic exposure associ-
ated with an increase in the incidence of CDI of 2.1 per
10,000 patient-days.29 These data are consistent with the
findings from our study, and highlight the need for broad
antimicrobial stewardship focussing on a reduction in total
antibiotic exposure.
Most of the previous reports of CDI associated with CAP,
and indeed with specific antibiotics, have been in the
context of epidemics or outbreaks, and so have inherent
limitations and biases.30 Thus, the longitudinal nature of
this cohort is a particular strength. Although there have
been no previous longitudinal studies of CDI in CAP, Bruns
and colleagues described a prospective study of 107 pa-
tients with CAP with consecutive stool and skin cultures;
C. difficile was carried asymptomatically by 9.4% of pa-
tients on admission to hospital and was acquired by a
further 11.2% of patients while in hospital, although no
cases of active CDI were identified.31 The results of the
analysis by Bruns et al. and the present study agree, in
that while there was not a strong relationship between
choice of empiric antibiotic and acquisition of C. difficile,
prolonged antibiotic therapy and prior hospitalization
were the leading risk factors.31
The antibiotic classes most strongly associated with the
development of CDI include clindamycin and third-
generation cephalosporins; more recently, quinolones,
carbapenems and aminopenicillins have also been impli-
cated.32,33 Macrolides are widely used in CAP and can also
induce CDI because of their activity against gut anaer-
obes.34 Macrolides are rarely used as monotherapy, and
therefore, estimating their individual effect independent
of the cephalosporins or aminopenicillins is challenging.
Although interaction testing suggested no significant differ-
ence in risk between the individual antibiotics evaluated in
the present study, macrolides and amoxicillin/clavulanic
acid had the highest HR, and our data suggest that addition
of macrolides to b-lactam therapy was associated with an
increased risk of CDI. However the relationship was only
statistically significant for the addition of clarithromycin
to amoxicillin/clavulanic acid, and it should be noted that
study power to detect independent effects of macrolides
was limited. If macrolide use is associated with CDI this
would be particularly interesting in light of recent data sug-
gesting that, outside the intensive care unit, the addition of
macrolides to b-lactams for CAP may not improve out-
comes. A cluster-randomized trial in the Netherlands
demonstrated no advantage for mortality of adding of mac-
rolides compared with b-lactam monotherapy.35
The present study identified duration of antibiotic
therapy as a key risk factor for CDI. Antibiotic regimens
as short as 3 days may be as effective as longer courses in
the majority of patients with mild-to-moderate CAP.36,37
Despite this evidence, a recent international audit reported
the mean duration of antibiotic treatment for hospitalized
patients to be 10e11 days.38 One of the most striking find-
ings of the audit was a lack of association between pneu-
monia severity and the duration of antibiotic therapy,
indicating that treatment duration is often a matter of
practice and convention rather than being based on objec-
tive measures of treatment response.38 Shorteningantibiotic treatment duration can have multiple benefits,
including reduced side effects, reduced hospital costs,
shortened length of stay, and reduced likelihood of devel-
oping antimicrobial resistance. The effects of a multidisci-
plinary programme to reduce antibiotic duration were
demonstrated in a recent prospective before-and-after
intervention study in 502 patients with lower respiratory
tract infections. The programme, which incorporated anti-
biotic treatment duration based on the CURB65 score, auto-
matic stop dates, and pharmacist feedback to prescribers,
significantly reduced the duration of antibiotic treatment
by 18% (P < 0.001) and the incidence of treatment-
related adverse events by 39% (PZ 0.03), with no increase
in mortality or length of stay.39
Well-established clinical stability criteria and a reduc-
tion in C-reactive protein levels can identify patients who
have responded to treatment and are thus at low risk of
complications.40 Once stability has been reached, discon-
tinuing antibiotic therapy early appears to have a good
safety profile, while efficacy is not diminished compared
with longer treatment durations.40 This is clearly an area
for further investigation, as reducing length of antibiotic
therapy may reduce CDI risk.
Notably, this study used the Techlab C. difficile Tox A/B
II EIA to define CDI cases, which has been demonstrated to
be the most sensitive toxin EIA available.5,41 Thus, while
some CDI cases may have been missed, we believe that
within the confines of real-world testing, the conclusions
we have drawn are valid.
Our study demonstrates that CDI is a relatively uncom-
mon complication of CAP, occurring predominantly in
elderly patients with comorbidities. The development of
CDI in patients with CAP is associated with increased 30-day
and 1-year mortality. Moreover, because CAP is the most
common community-acquired infection requiring hospital-
ization in developed countries, its contribution to the
current global CDI epidemic is considerable. CDI is poten-
tially preventable, and our study suggests that reducing
total antibiotic exposure, limiting treatment duration and
reducing the length of hospital stay may be at least as
important as changing antibiotic class in reducing disease
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